Prospective Evaluation of Risk-Appropriate Management of Uveal Melanoma Patients Informed by Gene Expression Profiling

• DOI: 10.2217/mmt-2020-0001
• Publication Date: 2020-03-11T14:41:39Z
• Authors: Amy C Schefler; Alison Skalet; Scott C N Oliver; John Mason; Anthony B Daniels; Katherina M Alsina; Kristen M Plasseraud; Federico A Monzon; Brian Firestone
• Keywords: Short Communication; DecisionDx-UM; imaging; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; gene expression profiling; surveillance; uveal melanoma; ocular melanoma; RC254-282

The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort.Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected.A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance.Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.